NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against β-lactamase-producing strains

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 5, 2002, Pages 1262-1268

  Li, Qing ^a   Lee, Jean Y ^a   Castillo, Rosario ^a   Hixon, Mark S ^a   Pujol, Catherine ^a   Doppalapudi, Venkata Ramana ^a   Shepard, H Michael ^a   Wahl, Geoffrey M ^a   Lobl, Thomas J ^a   Chan, Ming Fai ^a  

^a NewBiotics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CLAVULANIC ACID; DIPHENYLMETHYL 7 (2 THIENYLACETYLAMINO) 3 [5 CHLORO 2 (2,4 DICHLOROPHENOXY)PHENOXYMETHYL] 3 CEPHEM 4 CARBOXYLATE; NB 2001; TRICLOSAN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG POTENCY; DRUG STRUCTURE; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENZYME MECHANISM; GENE OVEREXPRESSION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ANALYSIS;

BACTERIAL INFECTIONS; BETA-LACTAMASES; CEPHALOSPORINS; DRUG DESIGN; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; HYDROLYSIS; MICROBIAL SENSITIVITY TESTS; PRODRUGS; TRICLOSAN;

EID: 0036232926     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.5.1262-1268.2002     Document Type: Article

References (32)

1. Role of the omega-loop in the activity, substrate specificity, and structure of class A β-lactamase
2. Triclosan: Applications and safety
3. New β-lactamases in gram-negative bacteria: Diversity and impact on the selection of antimicrobial therapy
4. Mechanisms of resistance to β-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993
5. The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit
6. Mechanism of triclosan inhibition of bacterial fatty acid synthesis
7. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis
8. Bacterial resistance: A worldwide problem
9. Differences between clavulanic acid and sulbactam in induction and inhibition of cephalosporinases in enterobacteria
10. Molecular evolution of bacterial β-lactam resistance
11. Molecular basis of triclosan activity
12. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: Active efflux as a contributing factor to β-lactam resistance
13. β-lactamases in laboratory and clinical resistance
14. Clavulanate and β-lactamase induction
15. Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance
16. β-lactamases
17. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics
18. Methicillin-resistant staphylococcal colonization and infection in a long-term care facility
19. Methicillin-resistant Staphylococcus aureus: A consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management
20. Antibiotic resistance
21. Streptococcus pneumoniae
22. Multiantibiotic resistance caused by active drug extrusion in Pseudomonas aeruginosa and other gram-negative bacteria
23. The crisis in antibiotic resistance
24. Inhibitor-resistant β-lactamases
25. Mechanisms of bacterial antibiotic resistance
26. Methicillin-resistant Staphylococcus aureus: Microbiologic characteristics, antimicrobial susceptibilities, and assessment of virulence of an epidemic strain
27. Teaching microbiology to medical students
28. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: Impact of intravascular devices and methicillin resistance
29. Staphylococcus aureus
30. Penicillin-binding proteins and the mechanism of action of β-lactam antibiotics